CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | PC0172-000 |
|---|---|
| Brand Name | Nerlynx |
| Generic Name | Neratinib |
| Strength | 40 mg |
| Tumour Type | Breast |
| Indication | Hormone Receptor-Positive Breast Cancer |
| Funding Request | For patients with HER2-positive, hormone receptor-positive breast (HR-positive) cancer who have completed adjuvant trastuzumab-based therapy within the past 12 months |
| Review Status | Complete |
| Pre Noc Submission | Yes |
| NOC Date | July 16, 2019 |
| Manufacturer | Knight Therapeutics Inc. |
| Sponsor | Knight Therapeutics Inc. |
| Submission Date | April 18, 2019 |
| Submission Deemed Complete | May 3, 2019 |
| Submission Type | Initial |
| Prioritization Requested | |
| Stakeholder Input Deadline ‡ | May 3, 2019 |
| Check-point meeting | July 4, 2019 |
| pERC Meeting | September 19, 2019 |
| Initial Recommendation Issued | October 3, 2019 |
| Feedback Deadline ‡ | October 18, 2019 |
| pERC Reconsideration Meeting | November 21, 2019 |
| Final Recommendation Issued | December 5, 2019 |
| Notification to Implement Issued | December 20, 2019 |
| Therapeutic Area | ERBB2-positive breast cancer |
| Recommendation Type | Do not reimburse |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
